一、 董事会会议召开情况 本公司及董事会全体成员保证信息披露内容的真实、准确、完整、没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300841 证券简称：康华生物 公告编号：2025-057 成都康华生物制品股份有限公司 第三届董事会第九次会议决议公告 （二）审议通过《关于修订<公司章程>的议案》 二、 董事会会议审议情况 同时董事会提请股东大会授权公司法定代表人或法定代表人指定的授权代 理人办理本次修订《公司章程》等相关的工商变更登记事宜。授权的有效期限自 股东大会审议通过之日起至本次修订《公司章程》等相关工商变更登记办理完毕 之日止。本次变更具体内容最终以工商登记为准。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）披露的《关于调 整公司治理结构、修订<公司章程>及制定、修订、废止部分公司治理制度的公 告》（公告编号：2025-059）。 （一）审议通过《关于豁免第三届董事会第九次会议通知时限的议案》 表决结果：同意票 8 票，反对票 0 票，弃权票 0 票。 各位董事在充分了解《公司法》《公司章程》及《董事会议事规则》中关于 召开董事会临时会议的通知要求以及董事权利的内容基础 ...

Core Viewpoint - The biopharmaceutical sector experienced a decline of 0.37% on November 7, with He Yuan Bio leading the drop. The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1]. Group 1: Stock Performance - Wan Ze Co. (000534) saw a significant increase in stock price, closing at 22.51 with an 8.80% rise and a trading volume of 754,200 shares, amounting to 1.681 billion yuan [1]. - Tibet Pharmaceutical (600211) closed at 46.05, up 2.74%, with a trading volume of 80,600 shares, totaling 371 million yuan [1]. - Anke Bio (300009) increased by 2.25%, closing at 10.93 with a trading volume of 442,300 shares, amounting to 482 million yuan [1]. - The overall biopharmaceutical sector saw a net outflow of 678 million yuan from institutional investors, while retail investors had a net inflow of 304 million yuan [2][3]. Group 2: Capital Flow - The main capital inflow was observed in Tibet Pharmaceutical, with a net inflow of 26.13 million yuan from institutional investors, while retail investors had a net outflow of 36.64 million yuan [3]. - Anke Bio also experienced a net inflow of 23.91 million yuan from institutional investors, with retail investors seeing a net outflow of 13.09 million yuan [3]. - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with institutional investors pulling back while retail investors showed some interest [2][3].

Core Viewpoint - Kanghua Biotech has completed the transfer of shares to Shanghai Wankexin Biotechnology Partnership, resulting in a change of controlling shareholder to Wankexin Biotech, with no actual controller remaining in the company [1] Group 1 - Wang Zhentao and his concerted parties, including Aokang Group and Jinan Kangyue Qiming Investment Partnership, have successfully transferred shares of Chengdu Kanghua Biotech Co., Ltd. to Wankexin Biotech [1] - The share transfer has been officially registered with China Securities Depository and Clearing Corporation Limited [1] - Following the completion of the share transfer, the controlling shareholder of the company has changed to Wankexin Biotech, indicating a shift in ownership structure [1]

Core Viewpoint - Kanghua Biotech (300841.SZ) has announced a change in its controlling shareholder to Wanke Xin Biological Technology Partnership, with no actual controller remaining in the company [1] Summary by Relevant Sections - **Shareholder Change** - Wang Zhentao and his concerted parties, including Aokang Group and Jinan Kangyue Qiming Investment Partnership, have completed the transfer of shares to Shanghai Wanke Xin Biological Technology Partnership [1] - **Completion of Transfer** - The share transfer has been officially registered with the China Securities Depository and Clearing Corporation Limited, marking the completion of the ownership change [1] - **Corporate Control** - Following the transfer, Wanke Xin Biological becomes the controlling shareholder, and the company will operate without an actual controller [1]

证券代码：300841 证券简称：康华生物 公告编号：2025-056 成都康华生物制品股份有限公司 关于控股股东、实际控制人及其一致行动人、持股 5%以上 股东协议转让股份过户完成及部分股份解除质押 暨公司控制权发生变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2、本次协议转让股份完成过户登记后，公司控股股东变更为万可欣生物， 公司无实际控制人。 近日，公司收到王振滔先生及奥康集团通知，其质押的部分股份已解除质押， 王振滔先生、奥康集团、康悦齐明向万可欣生物协议转让公司股份事宜已取得深 圳证券交易所出具的确认意见，并已在中国证券登记结算有限责任公司办理过户 登记手续，取得了《证券过户登记确认书》。现将具体情况公告如下： 一、本次协议转让股份事项基本情况 2025 年 7 月 18 日，王振滔先生、奥康集团、康悦齐明与万可欣生物签署了 《股份转让协议》，王振滔先生与万可欣生物签订了《表决权委托协议》。根据 《股份转让协议》，王振滔先生、奥康集团、康悦齐明合计向万可欣生物转让所 持有的公司 2,846.6638 万股股份，占《股份转让协议》签订之日 ...

Core Viewpoint - Kanghua Biotech's stock has shown significant growth this year, with a 51.82% increase, despite a decline in revenue and net profit for the first nine months of 2025 [1][2]. Group 1: Stock Performance - On November 7, Kanghua Biotech's stock rose by 2.01%, reaching 81.29 CNY per share, with a trading volume of 2.09 billion CNY and a turnover rate of 2.21% [1]. - The company's market capitalization stands at 10.563 billion CNY [1]. - Year-to-date, the stock has increased by 51.82%, with a 5.24% rise over the last five trading days, 5.57% over the last 20 days, and 4.03% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Kanghua Biotech reported a revenue of 840 million CNY, a year-on-year decrease of 20.78%, and a net profit attributable to shareholders of 189 million CNY, down 53.41% year-on-year [2]. - The company has distributed a total of 686 million CNY in dividends since its A-share listing, with 462 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased to 18,300, a rise of 6.13%, while the average number of circulating shares per person decreased by 8.10% to 6,502 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest with 1.1826 million shares, marking its entry as a new shareholder [3]. - The Southern CSI 1000 ETF is the seventh largest shareholder with 850,600 shares, having decreased its holdings by 11,000 shares compared to the previous period [3].

Market Overview - The biopharmaceutical sector experienced a decline of 0.96% on November 5, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 3969.25, up 0.23%, while the Shenzhen Component Index closed at 13223.56, up 0.37% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Jinke (688670) with a closing price of 18.09, up 3.37% [1] - Kanghua Bio (300841) at 79.20, up 1.93% [1] - Wuxi Jinghai (920547) at 27.87, up 1.46% [1] - Significant decliners included: - Buyuan Bio (688765) at 112.00, down 12.55% [2] - SanSheng Guojian (688336) at 70.10, down 8.47% [2] - Rongchang Bio (688331) at 92.00, down 4.90% [2] Trading Volume and Capital Flow - The biopharmaceutical sector saw a net outflow of 668 million yuan from institutional investors, while retail investors contributed a net inflow of 380 million yuan [2] - The trading volume for key stocks included: - Kanghua Bio with a trading volume of 43,600 shares and a transaction value of 345 million yuan [1] - Buyuan Bio with a trading volume of 185,800 shares and a transaction value of 2.206 billion yuan [2] Capital Inflow Analysis - Major stocks with net inflows from institutional investors included: - Kanghua Bio with a net inflow of 40.48 million yuan, accounting for 11.72% of its trading volume [3] - Hualan Bio with a net inflow of 31.05 million yuan, accounting for 4.66% [3] - Conversely, stocks like Jinke experienced a net outflow of 13.56 million yuan from retail investors, representing 17.39% of its trading volume [3]

Group 1 - The core viewpoint of the news is that Kanghua Biological has seen a 5% increase in stock price, reaching 77.25 yuan per share, with a trading volume of 203 million yuan and a turnover rate of 2.24%, resulting in a total market capitalization of 10.038 billion yuan [1] - Kanghua Biological, established on April 2, 2004, and listed on June 16, 2020, is primarily engaged in the comprehensive research, development, and operation of vaccines, with 99.99% of its main business revenue coming from non-immunization planning vaccines [1] Group 2 - Among the top ten circulating shareholders of Kanghua Biological, a fund under Southern Fund holds a position. The Southern CSI 1000 ETF (512100) reduced its holdings by 11,100 shares in the third quarter, now holding 850,600 shares, which accounts for 0.72% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 76.63 billion yuan. Year-to-date returns are 27.12%, ranking 2130 out of 4216 in its category, while the one-year return is 25.9%, ranking 2007 out of 3889 [2] - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has been in the position for 6 years and 360 days, managing total assets of 122.76 billion yuan, with the best fund return during the tenure being 182.39% and the worst being -15.93% [2]

Core Insights - The company reported significant growth in revenue and profit for the third quarter of 2025, driven by increased demand in consumer-grade laser products and the new energy sector [1][3]. Financial Performance - Total revenue for the first three quarters reached 1.509 billion yuan, a year-on-year increase of 41.02% [1][2]. - Net profit attributable to shareholders was 204 million yuan, up 97.30% year-on-year [1][2]. - The gross profit margin stood at 40.58% [1]. - In Q3 alone, revenue was 628 million yuan, reflecting a 31.90% year-on-year growth and a 16.83% quarter-on-quarter increase [2][3]. - The net profit for Q3 was 109 million yuan, showing a year-on-year increase of 123.78% and a quarter-on-quarter increase of 83.53% [2][3]. Research and Development - R&D investment totaled 141 million yuan in the first three quarters, representing a 12.98% increase and accounting for 9.36% of total revenue [3]. Market Demand and Product Development - The growth in performance is attributed to rising demand for laser products in consumer markets and the recovery of smart equipment needs [3]. - The company is experiencing a transition in consumer-grade lasers from blue lasers to fiber lasers, with increasing consumer demand for faster and more precise laser processing [3]. - The company has secured bulk orders for laser products used in laser engraving machines and is expected to achieve mass shipments for 3D printing equipment [3]. Strategic Collaborations - In 2025, the company will collaborate with Yushui Optoelectronics to develop a new generation of silicon photonic wafer-level testing systems, targeting the growing overseas market [4]. - The company has received bulk orders for its FPC micro-hole processing drilling system from leading industry clients [4]. Optical Communication Sector - The company has launched new products in the optical communication field, including MPO fiber connectors and fiber array units (FAU), with ongoing expansion to meet customer demand [5]. - The FAU from the company's subsidiary, Matrix Optoelectronics, has begun bulk shipments to leading domestic optical module manufacturers [5].

详式权益变动报告书 成都康华生物制品股份有限公司 详式权益变动报告书 成都康华生物制品股份有限公司 （修订稿） 上市公司名称：成都康华生物制品股份有限公司 信息披露义务人：上海万可欣生物科技合伙企业（有限合伙） 住所：中国（上海）自由贸易试验区张江路 58、92 号 18 幢 通讯地址：中国（上海）自由贸易试验区张江路 58、92 号 18 幢 权益变动性质：增加（协议转让、表决权委托） 签署日期：二〇二五年十月 成都康华生物制品股份有限公司 详式权益变动报告书 修订说明 信息披露义务人已于 2025 年 7 月 23 日公告了《成都康华生物制品股份有限 公司详式权益变动报告书》，现基于本次权益变动涉及的相关事项发生变化，信 息披露义务人对本次权益变动相关情况进行修订，本次主要修订内容如下。 一、根据信息披露义务人最新的工商登记情况，对相关内容进行修订 详见本报告之 "第二节 本次权益变动决定及目的"之"一、信息披露义务 人基本情况"。 股票上市地点：深圳证券交易所 股票简称：康华生物 股票代码：300841.SZ 1 成都康华生物制品股份有限公司 详式权益变动报告书 详见"第五节 资金来源"之"二、本次权益 ...